Century Therapeutics reports Q3 2026 results, two lead programs on track for clinic
Century said CNTY-813 remains set for an IND filing in the fourth quarter of 2026 and CNTY-308 is still expected to enter the clinic this year, with cash extending into early 2029.
SEC filing